Core Insights - Annovis Bio Inc. is participating in the 13th Alzheimer's & Parkinson's Drug Development Summit from March 18-20 in Boston, focusing on transformative therapies for neurodegenerative diseases like Alzheimer's and Parkinson's [1][2] Company Overview - Annovis Bio is a late-stage clinical drug platform company headquartered in Malvern, Pennsylvania, dedicated to developing innovative therapies aimed at improving patient outcomes in neurodegenerative diseases [3] Event Participation - The company will present findings from its Phase III clinical trials of Buntanetap and discuss a holistic approach to treating neurodegenerative diseases, emphasizing the need to address multiple neurotoxic proteins rather than focusing on a single target [2] - Annovis will participate in a panel discussion on March 19, exploring opportunities in targeting alpha-synuclein and the future of Parkinson's drug development [2] Research Focus - The summit aims to provide comprehensive coverage of the drug development process, from early discovery to late-stage development, with a focus on novel therapeutic targets for neurodegenerative diseases [2]
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment